These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6814753)

  • 1. Monoclonal anti-MM46 antibody:ricin A chain conjugate: in vitro and in vivo antitumor activity.
    Seto M; Umemoto N; Saito M; Masuho Y; Hara T; Takahashi T
    Cancer Res; 1982 Dec; 42(12):5209-15. PubMed ID: 6814753
    [No Abstract]   [Full Text] [Related]  

  • 2. [In vitro and in vivo antitumor activity of monoclonal anti-MM46 antibody-ricin A chain conjugate].
    Takahashi T; Seto M; Hara T
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1894-1900. PubMed ID: 6882010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preparation and anti-tumor activity of monoclonal antibody against ascitic mammary tumor MM46 cells].
    Takahashi T; Seto M; Hara T
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):544-50. PubMed ID: 6192760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
    Raso V; Ritz J; Basala M; Schlossman SF
    Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytotoxicity of a conjugate of ricin A-chain and monoclonal anti-allotypic antibody].
    Rachmanova VA; Tonevitskiĭ AG; Cherapakhin VV; Bobreneva RA
    Biull Eksp Biol Med; 1988 May; 105(5):568-70. PubMed ID: 3132992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selective cytotoxicity of an antibody-ricin A chain conjugate for human tumor cells].
    Tonevitskiĭ AG
    Mol Biol (Mosk); 1985; 19(4):1034-41. PubMed ID: 4047033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge.
    Lemley PV; Wright DC
    Immunology; 1992 Jul; 76(3):511-3. PubMed ID: 1526657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thy 1.2+ leukemia cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates.
    Colombatti M; Colombatti A; Blythman HE; Bron C
    J Natl Cancer Inst; 1984 May; 72(5):1095-9. PubMed ID: 6585586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective cytotoxic effect of immunotoxin on erythroid tumor cells of mice].
    Tonevitskiĭ AG; Mechetner EB; Rozinova EN; Ievleva ES
    Dokl Akad Nauk SSSR; 1985; 282(2):485-8. PubMed ID: 3860370
    [No Abstract]   [Full Text] [Related]  

  • 10. Specific cytotoxicity of a human immunoglobulin-directed Fab'-ricin A chain conjugate.
    Raso V; Griffin T
    J Immunol; 1980 Dec; 125(6):2610-6. PubMed ID: 7430640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of murine tumor with syngeneic antitumor serum plus BCG.
    Yamazaki M; Saito M; Abe S; Mizuno D
    Jpn J Exp Med; 1983 Feb; 53(1):27-32. PubMed ID: 6876475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A monoclonal immunotoxin against laryngeal carcinoma cells.
    Zenner HP
    Otolaryngol Pol; 1990; 44(3):214-5. PubMed ID: 2255554
    [No Abstract]   [Full Text] [Related]  

  • 15. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V; Engert A; Schnell R; Vitetta ES
    Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present potential of immunotoxins.
    Poncelet P; Blythman HE; Carriere D; Casellas P; Dussossoy D; Gros O; Gros P; Jansen FK; Laurent JC; Liance MC
    Behring Inst Mitt; 1984 May; (74):94-100. PubMed ID: 6383330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigens on naturally occurring animal and human tumors detected by monoclonal antibodies.
    Embleton MJ; Gunn B; Byers VS; Baldwin RW
    Transplant Proc; 1981 Dec; 13(4):1966-9. PubMed ID: 6949387
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of a monoclonal F(ab')2:ricin A conjugate for retinoblastoma in vitro.
    Merriam JC; Lyon HS; Char DH
    Cancer Res; 1984 Aug; 44(8):3178-83. PubMed ID: 6744258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.